Know Cancer

or
forgot password

A Double-blind, Randomized, Vehicle-controlled Phase II Study to Determine the Effects of Concomitant Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region


Phase 2
18 Years
N/A
Not Enrolling
Both
Oral Mucositis

Thank you

Trial Information

A Double-blind, Randomized, Vehicle-controlled Phase II Study to Determine the Effects of Concomitant Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region


Inclusion Criteria:



1. Patient is 18 years of age or older;

2. Patient has a histologically documented diagnosis of cancer of the head and neck
region;

3. Patient is about to receive a course of radiation therapy (with or without
concomitant chemotherapy) with a planned dose of at least 60 Gy over 6-7 weeks, and
with planned fields to involve at least 50% of the oral mucosa;

This criterion was amended (Amendment 01 dated August 28, 2000) to read as follows:

3. Amended: Patient is at a high risk of developing radiation-induced mucositis. For the
purpose of this study, high-risk patients will be defined as:

1. patients about to receive a course of radiation therapy (with or without concomitant
chemotherapy) with a planned dose of at least 60 Gy over 6-7 weeks, and

2. with planned fields to involve at least 40% of the oral and oropharyngeal mucosa
visible by direct inspection;

4. Patient has a Karnofsky Performance Scale (KPS) score of 60% or more;

5. Patient is willing and able to cooperate with the protocol including rinsing of
the oral cavity with the investigational or vehicle oral rinse 6 times per day.

6. The patient or guardian is capable of providing informed consent.

7. If female, the subject has undergone a urine pregnancy test with negative results,
and has agreed to practice effective methods of contraception for the duration of the
study.

Exclusion criteria

1. Patient has had previous radiation therapy to the oral mucosa;

2. Patient is about to receive hyperfractionated radiation therapy;

3. Patient has active oral H. simplex lesions, oral candidiasis, or oral mucositis
due to other disease processes;

4. Patient has uncontrolled infection;

5. Patient has HIV, Hepatitis B (HBV) (as measured by HBs-Ag) or Hepatitis C (HCV)
infection;

6. Patient has not recovered from oral toxicity attributable to prior treatment;

7. Patient has abnormal laboratory values that meet the following criteria:

- Serum creatinine greater than 2 x upper limit of normal

- Total bilirubin greater than 3 x upper limit of normal;

- SGOT greater than 3 x upper limit of normal;

- LDH greater than 3 x upper limit of normal;

8. Patient has known sensitivities to any of the study preparation ingredients;

9. Patient has participated in a clinical research study within the last 30 days
prior to enrollment;

10. Patient is unable to communicate or cooperate with the investigator due to
language problems, poor mental development, or other reasons.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Outcome Measure:

Evaluation of mucositis using the Oral Mucositis Assessment Score

Outcome Time Frame:

7 weeks

Safety Issue:

No

Principal Investigator

Paul Busse, M.D., Ph.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Beth Israel Deaconess Medical Center

Authority:

United States: Food and Drug Administration

Study ID:

AP-C-9U01

NCT ID:

NCT01083875

Start Date:

February 2000

Completion Date:

June 2001

Related Keywords:

  • Oral Mucositis
  • Radiation
  • mucositis
  • head and neck carcinoma
  • oral rinse
  • amlexanox
  • MuGard
  • Head and Neck Neoplasms
  • Stomatitis
  • Mucositis

Name

Location

Beth Israel Deaconess Medical CenterBoston, Massachusetts  02215
Loyola University Medical CenterMaywood, Illinois  60153
Mobile Infirmary Medical CenterMobile, Alabama  36640-0460
University of Connecticut Health CenterFarmington, Connecticut  06360-7106
Arlington Cancer CenterArlington, Texas  76012
Corpus Christi Cancer CenterCorpus Christi, Texas  78412
St. Thomas HospitalNashville, Tennessee  37205
Wayne State University School of MedicineDetroit, Michigan  48201-2097
University of TennesseeMemphis, Tennessee  38163
University of Arkansas Medical SchoolLittle Rock, Arkansas  72205
Florence Wheeler Cancer CenterBakersfield, California  93301
ICSL Clinical StudiesMelbourne, Florida  32935